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1. INTRODUCTION 
 
1.1. Diabetes Mellitus (DM) 
Diabetes mellitus is one of the most common and challenging 
disease conditions of 21st centuary. It is a chronic complex progressive and 
multisystemic disorder with life threatening micro and macrovacular 
complications1. WHO defined Diabetes mellitus as a metabolic disorder of 
multiple etiologies characterized by chronic hyperglycemia with 
disturbances in carbohydrate, fat and protein metabolism resulting from 
defects in insulin secretion, insulin action, or both2. It is a major cause of 
morbidity and mortality.  Prevalence of DM are about more than 150 
million diabetics across the world and more than one fifth of them are 
Indians. International Diabetes Federation, India has been declared India 
as "Diabetic Capital of the World" at the recent Conference in Paris3. 
Diabetes mellitus consists of a group of syndrome characterized by 
hyperglycemia, altered metabolism of lipids, carbohydrates, and proteins; 
resulting from defects in insulin secretion, its action, or both4. 
DM is a complex, heterogeneous and polygenic metabolic disease 
where there will be an absolute lack of insulin, decreased sensitivity to 
insulin or both and which results in abnormal glucose homeostasis and 
subsequent hyperglycemia. Mutual interaction between genetic and 
environmental factors plays an important role in the pathogenesis of 
diabetes mellitus5. DM Has been characterized by a variety of causes such 
asobesity, abdominal adiposity, genetic, ethnicity etc. 
Obesity and increased BMI have a great impact on diabetogenesis. 
The association between increased BMI and weight gain and risk of 
Diabetes mellitus is significant among Asians. Waist circumference (WC) 
cut point for Indians for any cardio- metabolic risk factors is 87cm for men 
and 82cm for women whereas that of BMI is 23 kg/m2 in both sexes5. It is 
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found that the developing countries adopt the western life styles like 
decreased physical activity and over consumption of cheap, energy dense 
food for past 20 years and as a result the rate of obesity has tripled in 
developing countries. Such changes have a direct influence on the child 
health of the country; the prevalence of obesity among them ranges from 2 
to 10% and the prevalence of overweight ranges from 10 to 25%6. 
DM has a strong genomic association, genome-wide association 
studies has catalogued a number of gene that have an influence on DM 
(with modest odds ratio ranges between 1.2 to 1.5) and they include 
TCF7L2, HHEX, CDKAL1, SLC30A8etc5. 
In India nearly 75% of the Type DM has first degree family history 
of diabetes indicating a strong familial aggregation. Prevalence of insulin 
resistance is found to be high in Asian Indians and they need higher 
amount of insulin to maintain normoglycemia. Comparison of Asian 
Indians, Europeans and other ethnic groups have shown that the former 
have higher insulin response than others, at fasting and in response to 
glucose. Asian Indians also have some factors which decreases the insulin 
sensitivity such as central obesity and high percentage of body fat in 
comparison to many other populations. 
Diabetes mellitus  (DM) currently is a major health problem of the 
world and due to chronic metabolic syndrome resulting from a variable 
interaction of hereditary and environmental factors and is characterized by 
abnormal insulin secretion or insulin receptor or post-receptor events, 
affecting metabolism involving carbohydrates, proteins and fats in addition 
to damaging liver, kidney and beta-cell of pancreas7. 
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1.2.  Ayurveda treatment for DM 
Ayurveda which means ‘Science of life’ has derived from the 
Sanskrit words ‘Ayur’ meaning life and ‘Veda’ meaning 
knowledge.Ayurveda is based on the concept that everything in the 
universe  has composed of five basic elements such as space, air, energy, 
liquid and solid and they are called The PanchaMahabhuta, or “five great 
elements”. Ayurveda believes in the theory of tridoshas, namely vata 
(ether and air), pitha (fire) and kapha (earth and water). Ayurveda aims to 
keep the structural and physiological entities in a state of equilibrium, 
which signifies good health. Any imbalance in tridosha may leads to 
disease. 
Diabetes mellitus and its clinical features were known to ancient 
Indian physicians and they reported an elaborate description of Diabetes 
mellitus and its management. Ayurvedic practitioners treat diabetes with a 
multi-pronged approach, using diet modification, Panchkarma to cleanse 
the system, herbal preparations, yoga and breathing exercises. 
The common herbs which can be used against diabetes include 
turmeric, neem, coccineaindica, amalaki, triphala, bitter gourd, rose apple, 
leaves of bilva, cinnamon, gymnema, fenugreek, bay leaf and aloe vera. 
The Ayurvedic preparations ‘Vasanta Kusumakar Ras’ and 
‘Chandraprabhavati’ are used to treat diabetes mellitus. Proprietary 
Ayurvedic medications are also used to treat diabetes8. 
In ayurveda, diabetes mellitus is known as ‘madhumeha’ (madhu 
means “honey” and meha means “urine”).  
Madhumeha is characterized by Deterioration of the body with 
impairment of vata (vatajaprameha). Since it deteriorates maximum of 
dhatus (body tissues) all the vital organs will be affected. Impaired 
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digestion leads to accumulation of certain specific digestive impurities in 
pancreas and thereby abnormal insulin production. Madhumeha is a 
Maharoga (major disease) lead to several complications like retinopathy, 
neuropathy, nephropathy, joint pain, impotency, sexual and urologic 
problems9. 
1.3. Prevalence of DM in India10 
India is currently experiencing an epidemic of diabetes mellitus. To 
study the consequences of diabetes and the importance of diabetic care in 
India we need a thorough study on Epidemiology of Diabetes in different 
regions of India. Epidemiology of diabetes in India has an extensive 
history. Long back a national study reported that prevalence of DM in 
urban areas was 2.1 % and that in rural area was 1.5%. The available 
studies show that there is a sharp rise in the prevalence of DM in both 
urban and rural areas, among these southern India having the sharpest 
increase. 
Although in rural India the prevalence of diabetes is much lower 
than in the urban population, even here the prevalence of diabetes is 
rapidly rising. Diabetes is fast becoming the epidemic of the 21st century. 
Type  diabetes, which is more prevalent (more than 90% of all DM 
cases) and the main driver of the diabetes epidemic, now affects 5.9% of 
the world's adult population with almost 80% of the total in developing 
countries. World Health Organization (WHO) reported that 32 million 
Indians had diabetes in the year 2000. The International Diabetes 
Federation (IDF) estimates the total number of diabetic subjects to be 
around 40.9 million in India and it will rise to 69.9 million by the year 2025. 
The earliest documented diabetes prevalence study of India was done in 
Calcutta (now Kolkata) in the year 1938. They found that only 1% of 
subjects have DM with glycosuria. In Bombay (now Mumbai) reports on 
test for detection of diabetes in large number of subjects were first 
available in 1959. Another population based study - National Urban 
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Diabetes Survey (NUDS) was conducted in six large cities from different 
regions of India in 2001. This study was done on 11,216 subjects aged 
over 20 years from all socio-economic strata.  
The WHO criterion was used for diagnosis diabetes after an Oral 
Glucose Tolerance Test using capillary blood. The study showed that the 
age standardized prevalence of type  diabetes was 12.1%. The 
prevalence was the highest in Hyderabad (16.6%), followed by Chennai 
(13.5%), Bengaluru (12.4%), Kolkata (11.7%), New Delhi (11.6%) and 
Mumbai (9.3%). The prevalence of IGT was 16.8% in Chennai, 14.9% in 
Bengaluru (formerly Bangalore), 29.8% in Hyderabad, 10% in Kolkata, 
10.8% in Mumbai and 8.6% in New Delhi. The Prevalence of Diabetes in 
India Study (PODIS) was carried out in 108 centers 
(49 urban and 59 rural) in different parts of India to look at the urban-rural 
differences in type 2 diabetes and glucose intolerance. 
The prevalence of DM was found to be more in urban areas of 
northern region. Urban area of Chandigarh was the first site to study the 
prevalence of DM in this region. The study conducted in rural areas 
reported that the prevalence of diabetes in a rural locality near Delhi was 
1.5 % in the year 1991. The prevalence has been reported to vary 
between 1.5% in Delhi (1991) and 3.7% in Nagpur (2007) in rural areas. 
Regarding urban prevalence, an increasing trend is observed in the 
northern part of India since late 1960's, which has escalated from 2.9% in 
Chandigarh (1966) to 20.1% in Jaipur (2007).  
The first study done in South India was a hospital based study at 
Vellore in 1964, which showed a prevalence of 2.5%. The study conducted 
in Hyderabad showed a high prevalence of 4.1%. However, the studies in 
rural areas were conducted since 1972. In 1984, house to house surveys 
were conducted in Tenali, a small town in Andhra Pradesh (urban) and 
rural population of Pondicherry (now Puducherry), which reported a 
prevalence of 4.7% and 1.8% respectively. The prevalence in south India 
has been reported to vary between 0.7% in Pondicherry to 19.5% in Kochi 
in urban areas, while the prevalence in rural areas range from 1.3% in 
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Trivandrum to 13.2% in Godavari. The Chennai Urban Rural Epidemiology 
Study (CURES) investigators had a unique opportunity to compare 
prevalence rates of diabetes in Chennai city with three earlier 
epidemiological studies carried out in the same city using similar methods. 
It has been shown that Indians have a younger age of onset of diabetes 
compared to other ethnic groups. 
The Chennai Urban Population Study (CUPS) and CURES state 
that prevalence of coronary artery disease was 21.4 per cent among 
diabetic subjects compared to 9.1 per cent in subjects with normal glucose 
tolerance. The Impaired Glucose Tolerance subjects showed 14.9 per cent 
of prevalence of CAD. It was also seen that there is a rising prevalence of 
atherosclerosis with an increased intimal medial thickness. 
The prevalence of diabetes in urban areas has increased from 2.3% 
in 1975 to 11.7% in the year 2000. The prevalence of diabetes in peri-
urban population was found to be 4.0%. Mumbai and Ahmedabad are the 
main site f study. Urban prevalence has an escalating trend from 1.5% 
(1963) to 9.3% in Mumbai (2001). A similar trend is observed in the rural 
areas - an increase from 3.9% in 1991 to 9.3% in 2006. 
1.4. Mechanism of diabetes mellitus induction2 
 1.  β- cell destruction (Type 1 diabetes - IDDM)       
 (a) Immune mediated       
 (b) Idiopathy 
2.  Insulin resistance (Type 2 diabetes - NIDDM) 
3.  Genetic defects of β- cell function       
 (a) Glucokinase 
 (b) Hepatocyte nuclear transcription factor – 4 α       
(c) Insulin promoter factor        
(d) Mitochondrial DNA        
(e) Proinsulin or insulin conversion  
4.  Genetic defects in insulin processing or insulin actions defects in         
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(a) Proinsulin conversion.        
(b) Insulin gene mutation        
(c) Insulin receptor mutation  
5. Exocrine pancreatic defects  
6.  Endocrinopathy 
(a) Acromegaly         
(b) Cushing syndrome        
(c) Hyperthyroidism        
(d) Pheochrmocytoma 
(e) Glucocanonama 
7.  Infections        
(a) Cytomegalovirus        
(b) Coxhacivirus 
8.  Genetic syndrome associated with diabetes        
 (a) Down‘s syndroo generate reactive oxygen species, which also 
contribute to DNA fragmentation. The formation of superoxide 
anions results from both STZ action on mitochondria and increased 
activity of xanthine oxidase. 
STZ induced DNA damage activates poly ADP ribosylation leading 
to the depletion of cellular NAD+ and ATP content and thereby inhibition of 
insulin biosynthesis and secretion. Calcium, which may also induce 
necrosis, does not seen to play a significant roleme 
(b) Kleinfelter‘s syndrome        
(c) Turner‘s syndrome 
9.  Drugs    
(a) Glucocorticoid         
(b) Thyroid hormone        
(c) Thiazides         
(d) Phenytoins 
1.5. Types of Diabetes 
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There are three main types of diabetes   
1.5.1 Type  Diabetes 
Insulin-dependent diabetes (IDDM; Type I diabetes) is one of the 
most common metabolic disorders characterized by pancreatic beta cell 
destruction, it may be due to autoimmune attack. Genetic and 
environmental factors play a part and HLA- DR3 and HLA-DR4 confer 
susceptibility to Type 1 Diabetes Mellitus. 
1.5.2 Type  Diabetes:  
Non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset 
diabetes. Resulting from the combination of resistance to insulin action, 
inadequate insulin secretion and excessive or inappropriate glucagon 
secretion. 
1.5.3 Gestational Diabetes: 
Gestational diabetes mellitus (GDM) affects ∼ 7% of all pregnancies 
and it may also be defined as carbohydrate intolerance during gestation. 
The condition can be associated with several maternal and fetal 
complications, such as macrosomia, birth trauma, cesarean section and 
hypocalcaemia, hypoglycemia and hyperbilirubinemia in newborns.  
1.6. Etiology/Contributing Factors 
 Insulin resistance in the hepatic and skeletal muscle, increased 
hepatic glucose synthesis, over production of free fatty acids and 
relative insulin deficiency. 
 Beta cells failure. 
 Contributing factors: 
 Obesity 
 Racial/ ethnic background. 
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 Age (onset of puberty is associated with increased insulin 
 resistance). 
 Sedentary lifestyle. 
 Genetic predisposition. 
 Conditions associated with insulin resistance, (e.g., polycystic ovary 
 syndrome)  
1.6.1 Risk Factors of Diabetes  
The risk factors for diabetes may be categorized as modifiable risk 
factors and non-modifiable risk factors. 
1.6.2 Modifiable Risk Factors 
 Obesity (via BMI and WHR) : A meta-analysis demonstrated the 
pooled relative risks for incident diabetes of 1.87 (95% confidence 
interval (CI): 1.67-2.10), 1.87 (95% CI: 1.58-2.20) and 1.88 (95% 
CI: 1.61-2.19) per standard deviation of body mass index, waist 
circumference and waist/hip ratio and these three results in obesity 
and may leads to diabetes.   
 
 Physical Inactivity: The protective effect of physical activity in 
subjects with an excessive BMI and elevated glucose levels; 
Diabetes can be prevented by physical activity and weight control in 
peoples with both normal and impaired glycemic control. 
 
 Plasma Lipids and Lipoproteins Level: There are reports like the 
blood level of LDL, VLDL, TGL are high and that of HDL is low in 
Diabetic people. According to American Diabetes Association LDL 
Cholesterol should be <100 mg/dl; HDL Cholesterol: >60 mg/dL; 
and Triglycerides: <150 mg/dl. 
 Hypertension: It has been reported that the incident of diabetes for 
 hypertensive patient is 2.21 greater. 
 
 Dietary Habits: It   is suggested that whole grains are rich resources 
of dietary fiber, fat, vitamin, antioxidant nutrients, minerals, lignans, 
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starch, and phenolic compounds that have been linked to the 
reduced risk of insulin resistance, dyslipidemia, obesity, T2DM, 
heart diseases and dietary fructose specifically increases de novo 
lipogenesis, promotes dyslipidemia, decreases insulin sensitivity, 
and increases visceral adiposity in overweight/obese adults.   
 
1.6.2 Non-modifiable Risk Factors 
 Family History: First degree family history of diabetes was found in 
an  approximate of 75% of the T2DM patients. 
 Genetic factors: Genome-wide association studies show a strong 
 association between genetic factor and Diabetes. 
 Low/High Birth Weight: Both Low and High Birth Weight are risk 
factors  of Diabetes. 
1.7 Pathophysiology of non-insulin dependent DM  (Type-II) 
 Type-2 diabetes mainly occurs due to insulin resistance and/or 
insulin deficiency. Insulin resistance result in the impaired insulin mediated 
glucose uptake in the peripheral tissues like muscle and fat, fail to 
suppress hepatic glucose production and TGL reuptake by fat cells. To 
overcome the insulin resistance, beta islet cells try to increase the amount 
of insulin secreted. Beta cell destruction reduces insulin production. 
Therefore DM-2 has to occur, two defects are necessary: insulin 
resistance and insulin deficiency relative to the resistance.     
 
 
 
 
 
Fig. No: 01: Pathophysiology of Type-II Diabetes mellitus 
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1.7.1 Clinical Manifestations of Type 2 Diabetes Mellitus:11 
 Polydipsia – increased thirst. 
 Polyphagia – increased hunger. 
 Polyuria – increased urine. 
 Slow healing infections. 
 Blurred vision. 
 Impotence in men 
1.7.2. Criteria 
 Overweight (BMI ≥ 85th percentile for age and gender, weight for 
height ≥ 85th percentile or weight ≥ 120% of ideal for height). 
Plus any two of the following risk factors:  
 Family history of type 2 diabetes in first- or second degree relative   
 Race/ethnicity (American Indian, African American, Hispanic, 
 Asian/Pacific Islander)  
 Signs of insulin resistance or conditions associated with insulin 
resistance  (acanthosisnigricans, hypertension, dyslipidemia, 
polycystic ovary  syndrome)  
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1.7.3 Age of initiation: 
Age 10 years or at onset of puberty if puberty occurs at a younger 
age. 
1.7.4. Frequency: 
Every 2 years. 
1.7.5. Test:  
Fasting plasma glucose is the preferred method for screening. 
* Clinical judgment should be used to test for diabetes in high-risk 
 patients who do not meet these criteria. 
1.8. Type 2 dm management in India 
The patient should receive appropriate medical care along with self-
management to keep the diabetes under control. The main treatment 
goals are  
1. To achieve optimal glycemic level. 
2. To reduce other cardiovascular risk factors, including hypertension, 
 hyperlipidemia, and overweight and obesity; and   
3. To diminish micro and macro vascular complications.   
 Diabetics are treated with oral hypoglycemic agents with 
appropriate diet and exercise. Some patients may require insulin therapy 
with or without oral hypoglycemic agents. 
 
 
1.9 Treatment12 
Fig. No : 02. Image showing the effect of different anti diabetic drugs 
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Table 01: Classification of Oral Hypoglycaemic Drugs 
ORAL HYPOGLYCAEMIC DRUGS 
Si 
No 
CLASS DRUGS 
1 Sulfonylureas 
First generation; 
Tolbutamide, Chlorpropamide. 
Second generation; 
Glibenclamide, Glipizide 
2 Biguanide Metformin, Gliclazide, Glimepiride 
3 
Meglitinide/Phenylalanine 
analogues 
Repaglinide, Nateglinide 
4 Thiazolidinediones Rosiglitazone, Pioglitazone 
5 Glucosidase inhibitors Acarbose, Miglitol 
6 
Dipeptidyl peptidase-4 
(DPP-4) inhibitor 
SitagliptinVildagliptin 
 
 
1.9.1 Sulfonylureas  
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Drugs: Tolbutamide, chlorpropamide these are the drugs in the first 
generation. In second generation drugs like glibenclimide, glipizide, 
gliclazide and glimepiride. 
1.9.2 Side Effects  
•  Low blood sugar, 
•  An upset stomach, 
 •  Skin rash or itching, 
•  Weight gain.  
 
1.9.3 Biguanides 
 Drugs: Metformin 
 
1.9.4 Side Effects 
 
• Abdominal pain   
• Nausea  
• Metallic taste  
• Mild diarrhea  
• Anorexia  
1.9.5 Alpha-glycosidase inhibitors 
Drugs: Acarbose and miglitol 
1.9.6  SideEffects 
 May cause stomach problems such as gas, bloating and 
diarrhea 
1.9.7  Thiazolidinediones Drugs 
Drugs:Pioglitazone and troglitazone 
 
1.9.8  Side Effects  
• Plasma volume expansion  
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• Edema  
• Weight gain Headache 
• Myalgia  
• Mild anemia 
1.9.9 Meglitinides 
 Drugs: Repaglinide and nateglinide 
1.9.10  Side Effect 
• Weight gain  
• Low blood sugar 
1.10 Medical nutrition therapy 11 
A meal plan with regular meals and snacks and carbohydrate goals 
that are moderately less than their usual intake will often help lower the 
elevated blood.Since most of the teens diagnosed with type  diabetes are 
obese, they have to identify carbohydrate-containing foods and monitor 
carbohydrate intake thereby cessation of weight gainmay occur.  
 
1.10.1 General Guidelines for Food Intake 
 Eat 3 meals and 1 snack on a regular schedule. 
 Try not to skip meals. 
 Follow carbohydrate goals for meal planning from the dietitian.  
 Try to eat about the same amount of carbohydrate at the same time 
 each  day. 
 Decrease saturated fat intake. 
 Work towards a healthy weight. 
 Eat smaller portions at meals. 
 
 
1.10.2 Ways to Limit Carbohydrate Intake 
 Drink calorie-free beverages (e.g., water, tea, diet soda). 
Introduction 
 
 
16 
 Limit fruit juice to 1 cup/day. 
 Limit carbohydrate servings to 3-4/meal. If necessary decrease to 
 1-2 at  breakfast. 
 Check blood glucose level 2 hours after eating. (If >180 mg/dl, you 
 ate more carbohydrate than your body could handle). 
1.10.3 Benefits of Exercise 
 Helps you feel better and increases your energy  
 Reduces HbA1c 
 Improves insulin sensitivity 
 Helps in reaching a healthy weight  
 Increases strength and flexibility 
 Decreases risk factors for heart disease  
 Educes body fat and increases muscle mass1 
The aim of treatment is to maintain glycemic level with in normal 
range. Additional considerations are:  
• Maintain healthy weight. 
• Minimize hyperglycemia and hypoglycemia.  
• Achieve normal lipid levels. 
• Prevent and delay complications. 
• Promote optimal health and well-being.  
Treatment regimen depends on the type of diabetes, medical 
nutrition therapy, frequent blood glucose monitoring to identify and 
evaluate blood glucose patterns, and comprehensive education in 
diabetes, self-management and decision-making skills at diagnosis and 
follow-up visits. Target blood glucose goals for teens are listed in Table 2. 
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Table 02 : Blood Glucose Goals for Adolescents 
Biochemical Index Normal Goal Action Indicated 
Average premeal BG (mg/dl)
  
<110 80-120 <80 or >140 
Average 2 hour postmeal 
BG  
for rapid-acting insulin only 
<120 150-180 >180 
Average bedtime BG 
(mg/dl) 
<120 100-140 <100 or >160 
Average 3:00 am BG 
(mg/dl) 
<110 80-100 <80 or >120 
HbA1c (%) <6 <7 >8 
Adapted from: Orr, DP. Contemporary management of adolescents with 
diabetes mellitus. Part 1: Type 1 diabetes. Adolescent Health Update 
2000;12(2), Table1, p 2. 
 
1.11 Medicinal Plants 
 Nature always stands as a golden ark to exemplify the 
outstanding phenomenon of symbiosis. The biotic and abiotic elements of 
the nature are all independent. The plants were indispensible to man, for 
his life. A nest of other useful products are supplied to him by the plant 
kingdom. Nature has provides a complete range of remedies to came an 
ailments of mankind. The knowledge of drugs has accumulated thoughts 
of years of a result of meaning inquisitive nature so that today we possess 
many affective of causing health care.Archaeological evidence indicates 
that the use of medical plants data of least the paleotic, approximately 
60,000 years age.In India, medicinal plants are widely used in traditional 
systems of medicine like Ayurvedic, Unani, Siddha and Homeopathy. India 
with it's valuable resources of natural flora has always been one of the 
richest sources of medicinal plants in the world. 
 
 
Introduction 
 
 
18 
1.11.1 Importance of herbal drugs 
Antidiabetic allopathic drugs have their own side effect & adverse 
events like hypoglycaemia, nausea, vomiting, hyponatremia, flatulence, 
diarrhoea or constipation, alcohol flush, headache, weight gain, lactic 
acidosis, pernicious anaemia, dyspepsia, dizziness, joint pain. So instead 
of allopathic drugs, herbal drugs are a great choice which is having more 
or less no side effect & adverse effects. Around 800 Indian herbs possess 
ant diabetic activity. Though complementary & alternative medicine (CAM) 
treatments are popular, scientific evidence support their application to 
diabetes care is scare. Instead of focusing on single modalities CAM 
practitioners prescribe complex, multi dietary intervention. Ayurvedic 
interventions may benefits patients with higher base line HbA1c value, 
warranting further research.14 
Natural origin and fewer side effectspromote the use of herbal 
drugs in bothdeveloping and developed countries. In the last few years 
there has been an exponential growth in the use of herbal drugs. Many 
traditional medicines in use are derived from medicinal plants, minerals 
and organic matter.According to World Health Organization (WHO) there 
are about 21,000 plants, which are used for medicinal purposes around 
the world. Among these 2500 species are found in India. Indiais called as 
botanical garden of the world because of the rich herbal medicine 
resources. Very recently, two exhaustive reviews have been published 
based on global literature survey on 150 plants and 343 plants from 
different parts of the world. some plants like Allium cepa (Onion, piyaj), 
Allium sativum (garlic, lasun), Syzygiumcumini (Syn. Eugenia jambolana; 
(black plum; jamun), Momordicacharantia (bitter gourd; karela) 
Gymemasylvestre (Gurmar), Pterocarpusmarsupium (Vijay-) sar) etc. are 
well noticed by scientists as well as laymen, in recent years 15. 
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Biological actions of the plant products used against diabetes are 
related to their phytochenistry. Herbal products or plant products are rich 
in phenolic compounds, flavonoids, terpenoids, coumarins, and other 
constituents which reduces the blood glucose levels16. 
Our Vedic literatures like CharakSamhita already report the use of 
herbs and herbal derivatives for treatment of diabetes mellitus. According 
to CharakSamhitsa more than 400 plants are used in 700 recipes which 
are used to treat diabetes mellitus in almost two thirds of the world 
population. A large number of in vivo studies have been conducted on 
animals to test the claimed activity have demonstrated the hypoglycemic 
property of many plants, already reported in various literatures. The plant 
families, including the species most studied for their confirmed 
hypoglycemic effects include, Leguminoseae, Lamiaceae, Liliaceae, 
Cucurbitaceae, Asteraceae, Moraceae, Rosaceae, Euphorbiaceae and 
Araliaceae17. 
1.12 Animal Models 13 
Streptozotocin or streptozocin or Izostazin or zanosar (STZ) is a 
synthetic glucopyranose derivative isolated by the fermentations of 
Streptomyces achromogenes which possess anti-tumor antibiotic activity.  
It can be used to induce both type 1 and type 2 diabetes. Chemically it is   
(2-deoxy-2-(3-methyl-3-nitrosoureido)-D-glucopyranose).The frequently 
used single i.v dose in adult rats to induce IDDM by immune system 
activation was found to be in between 40 and 60mg/kg. NIDDM can also 
be induced in rats by intravenous or intraperitoneal treatment with 
100mg/kg b.w.STZ on the day of birth. 
 
 STZ decrease insulin biosynthesis and secretion by impairing 
glucose oxidation. STZ at first abolished the B cell response to glucose. 
Temporary return of responsiveness than appears which is followed by its 
permanent loss and cells are damaged. STZ is taken up by pancreatic B 
cells via glucose transporter mainly GLUT-2. Intracellular action of STZ 
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causes in changes of DNA I pancreatic B cells compromising its 
fragmentation. Alkylation of DNA is the main reason for the STZ induced B 
cells death. 
 
 STZ inhibits the Krebs cycle and decreases oxygen consumption by 
mitochondria and strongly limit mitochondrial ATP production and cause 
depletion of this nucleotide in B cells. Augmented ATP dephosphorylation 
increases the supply of substrate for xanthine and enhances for uric the 
final product of ATP degradation.   
 
 STZ is a Nitric oxide (NO) donor and NO was found to bring about 
the destruction of pancreatic islet cells. Hence it produces DNA damage. 
STZ is however not a spontaneous nitric oxide donor. STZ was found to 
generate reactive oxygen species, which also contribute to DNA 
fragmentation. The formation of superoxide anions results from both STZ 
action on mitochondria and increased activity of xanthine oxidase. 
 
 STZ induced DNA damage activates poly ADP ribosylation leading 
to the depletion of cellular NAD+ and ATP content and thereby inhibition of 
insulin biosynthesis and secretion. Calcium, which may also induce 
necrosis, does not seen to play a significant role. 
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2.  LITERATURE REVIEW 
 
Mohammed Salem et al (2013).,14 studied the antioxidant and 
antibacterial activity of Tecoma stans leaves and branches against the 
growth of some human bacterial strains using the disc diffusion and 
minimum inhibitory concentration (MIC) methods and antioxidant activity 
using 2,2-dimethyl-1-picrylhydrazyl (DPPH) method. Very significant 
activities were exhibited by the samples. These findings provide scientific 
evidence to support traditional medicines uses of Tecoma stans and 
indicate a promising potential for the development of an antibacterial and 
antioxidant agent from T.stans  
 Kameswaran et al (2013).,15 studied Hepato protective activity of 
Tecoma stans extract against the liver injury induced by paracetamol, 
carbon tetrachloride and thioacetamide. Results revealed that the extracts 
significantly reduce the elevated serum levels of Asparate amino 
transferase, alanine amino transferase, alkaline phosphate and bilirubin. 
The ethanolic extract at the dose of 500 mg/ kg more effective than 250 
mg/kg but his excluded in paracetamol induced liver damage. In chronic 
liver injury induced by CCl4, ethanolic extracts at the dose of 500 mg/kg. 
P.O. was found to be more effective than the extract of the dose of 250 
mg/kg. Histological examination of the liver tissues supported the hepato 
protective activity of the extracts.  
Kameswaran Sugavanan et al (2012).,16 studied the CVS 
depressant potential of different extracts of Tecoma stans flowers. Namely 
chloroform, methanol and water on Albino mice of both sexes. The study 
conform that the different extracts of Tecoma stans flowers exhibit CNS 
depressant activity. 
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Amad Ali-Azzawi et al (2012).,17 studied the genotoxic potential of 
Tecoma stans by in vivo and  in vitro system. This study examined the 
genotoxic activity of aqueous and ethanolic extracts on bone marrow cells 
from BAL B/C mice through evalution of milotic index and chromosome 
aberration and cytotoxic effect of two extracts on mouse embryo fibroplast 
(MFF) cell line. No alteration in the total no. of chromosomal aberration 
were observed and percentage of miotic index at the concentrations tested 
remained unchanged. The higher concentrations of the plant extracts had 
a cytotoxic effect on MFF cell line. Both extracts had no significant 
elastogenic effect in vivo,but showed cytotoxic effects on mouse embryo. 
  Thirumal et al (2012).,18 studied the crude leaf extract of Tecoma 
stans. These were examined for their anticancer activity. To determine in 
vitro Anticancer activity, different concentration of crude extract were 
tested in MCD -  of cancer cell line by 3- (4,5- dimethylthiazole-2-yl)-2,5- 
dimethyl tetrazolium bromide (TT) assay. Tecoma stans leaf extract 
showed significant anti-proliferative activity and a dose dependant effect 
was observed. Minimum inhibition of 14.6% was shown by extract at 
concentration 7.5 g/ ml and maximum inhibition (95.9%) was observed at 
1000 g/ml. 
 
Govindappa et al (2012).,19 studied the antibacterial and 
antioxidant activity of  ethanol, methanol and aques extract of  Tecoma 
stans. These three solvent fractions possessed strong radical scavenging 
activity when analyzed using FRAP and DPPH. It was ranged from 
1443.79 to 3841.17 g/ml. The results indicate that the plant is a potential 
candidate to be used as an antimicrobial and antioxidant. 
 
Kameswaran et al (2012).,20 evaluated the anticancer activity of  
methanolic  flower extract of Tecoma standin vitro and in vivo methods. 
Extract was subjected to preliminary qualitative phytochemical 
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investigation by using standard procedures and In vitro antitumor activities 
were evaluated by the MTT Assay method using vero and HFP - 2 cell 
lines. The extract was subjected to in vivo anticancer activity using enrich 
as cities carcinoma (EAC) tumor model. The activity was assessed 
increase in life span, average increase body weight, changes in food 
intake, Tumor volume, tumor weight, variable cell count, non-variable cell 
count, PCV, total cell count and hematological studies. The potency of 
extract was compared with standard 5-flurouracil (20 mg/kg). In vitro  
anticancer activity was exhibited and significant cytotoxic activity against 
both cell lines, at different concentration. Oral administration of the 
extracts at the doses of 200 and 400 mg/kg, significantly (P<0.001) 
increase the survival time. Non-viable cell count, decreased the average 
body weight and food intake, viable cell count of the tumor bearing mice. 
After 14 days of inoculation, METS was able to release the changes in the 
haemotological parameters, protein and P<V consequent to tumor 
inoculation.  
Raju et al (2011).,21 received on the  ethno-pharmacological, 
phytochemical and therapeutic potential of Tecoma stans. An exhaustive 
survey of literature revealed that alkaloids, flavanoids, saponins, phenols, 
steroids, anthraquinone tannis, terpenes and glycosides constitute the 
major classes of phytoconstituentspresent in the plant. Pharmacological 
report revealed that is having antidiabetic, anticancer, antioxidant, 
antispasmodic, antimicrobial, antifungal properties and extensively used in 
the treatment of diabetes.  
Krishna et al (2009).,22 studied the phytochemical screening 
analysis of n-hexane, ethyl acetate, ethanol and aqueous extracts of 
Tecoma stans, which indicates, the presence of alkaloids, saponins and 
tannins, In the n-hexane extract, the  constituents were absent.  
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Lin et al (2008).,23 found that, the flavanoids  from the plant 
extractspossesssubstantial antimicrobial  and antioxidant activities. 
Socolwsji et al (2008).,24 studied the effects of temperature and 
light on the control of seed germination in Tecoma stands. The influence of 
constant temperature from 10-40°C, with 5°C intervals under the white 
light and darkness were tested. The optimum temperature for the seed 
germination were found to be between 25 and 30° C for both the light and 
dark treatment. The   maximal germination was reached in the range of 
19-38°C under the light and 20-40°C during the darkness. The seeds 
showed highest synchronization of the germination near the optimal 
temperatures. The germination in the field was tested under the two light 
conditions. The highest percent of germination occurred under the Canopy 
(69%). However under the Canopy, the seedling presented 1.9% of the 
recruitment, while under the direct sunlight, 96.9% results showed that   
T. stans seeds germinated well in open areas with the occurrence of high 
seedling recruitment indicating the invasion  potential of the speciesunder 
such light conditions. 
Gharib Naseri . et al (2007).,25 have reported  antispasmodic effect 
of Tecoma stans hydro alcoholic leaf extract on rat ileum. 
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3. AIM AND OBJECTIVE 
The diabetes mellitus prevalence was increased day by day, due to 
metabolic disorder, life style changes, improper food intake and less 
physical activity .symptoms of high blood sugar, left untreated, diabetes 
mellitus can cause many  complications . Synthetic drugs have many side 
effects and harmful to the health. Over the centuries, they are traditionally 
practicing medicinal plants used to the treatment for various diseases but 
no scientific validation. Several literatures are indicated that the herbal 
drugs have lesser side effects when compared to synthetic medicines. The 
TecomaStans(L)juss is not scientifically validated and which was 
traditionally practicing herb .The work provides scientific validation for use 
of leaf against diabetes mellitus. 
The current study is help to develop a plant based diabetic drug 
which will be evaluated by using invivo streptozocin induced diabetes in 
rats 
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5.  PLANT PROFILE 
5.1 Tecomastans (l.)Juss.exkunth 
Fig No:03. Palnt  of TecomaStans(L.)  
 
Kingdom : Plantae 
Sub kingdom : Tracheobionta 
Super division: Spermatophyta 
Division : Magnoliophyta 
Class  : Magnoliopsida 
Subclass : Asteridae 
Order  : Scrophulariales 
Family : Bignoniaceae 
Genus : Tecoma Juss. 
Species : Tecoma stans (L.) Juss.exKunth 
5.2 Vernacular names 
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Tamil  : Manjarali, Naagasmbagam, Soonnapati,Sornapati 
English : Trumpet Flower, Yellow Elder, Yellow Trumpet Bush. 
Spanish : Lluvia De Oro, Trompeta, Tronafrente, Tronadora 
French :  Tecomajaune 
Portuguese : Amarelinho, Ipê-Mírím 
Germany : Aufrechtetrompetenwinde 
Italy : tecomagiallo 
Pacific Islands :piti 
Tecomastans is a species of flowering perennial large shrub or 
small, much-branched, tree usually growing 1.5 to 5 m tall, but 
occasionally reaching up to 10 m in height in the trumpet 
vine family, Bignoniaceae, that is native to the  southern USA, Mexico, the 
Caribbean, Peru and Ecuador. Tecomastans is the official flower of 
the United States Virgin Islands and the floral emblem of the Bahamas. 
Yellow trumpet bush is an attractive plant that is cultivated as 
an ornamental. 
The plant is desirable fodder when it grows in fields grazed 
by livestock. Yellow trumpetbush is a ruderal species, readily colonizing 
disturbed, rocky, sandy, and cleared land and occasionally becoming 
an invasive weed. It is used as firewood and charcoal, in the construction 
of buildings and the leaf infusion can be taken orally for diabetes and 
stomach pains. A strong leaf and root decoction is taken orally as a 
diuretic, to treat syphilis or for intestinal worms. It is a strong shading plant 
and can be planted as a live hedge. 
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5.3 General description 
5.3.1 Stem 
Full and cylindrical. The younger stems are smooth, glabrous and 
greenish in colour. They are slightly quadrangular and turn pale brown or 
reddish-brown in colour as they age. The bark on the main stem is light 
brown to pale grey in colour, furrowed, and relatively rough in texture, 
covered in light greyish to brown barks. 
5.3.2 Leaf 
Fig No:04: Tecomastans(L.) Leaf 
 
Borne on petioles 3-5 cm long. Compound, opposite, 10-25 cm 
long, with 3-13 leaflets, but usually 3-7 leaflets. 
Leaflets lanceolate to elliptic, 2-10 cm long and 1-4 cm wide, apexlong-
acuminate, base cuneate. Margins irregularly and finely toothed. Both 
sides of the leaf blade are smooth and mostly glabrous, though a few hairs 
may be present on the undersides near the midrib. 
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Inflorescence: Erect or inclined several-flowered clusters (5-15 cm 
long), produced terminally (at the ends of the branches), and then later, in 
the leaf axils near the tips of the branches. 
5.3.3 Flowers 
Showy bright yellow, tubular (trumpet-shaped), borne on short 
pedicels somewhat curved or twisted. Corolla tube 3-5 cm long with five 
rounded lobes, 8-30 mm long. Presence of several faint reddish lines in 
the throat of the flower, which is slightly ridged and hairy. 
Fig. 5 : Flower of Tecomastans(L.) 
 
5.3.4. Fruits 
The fruits are large, linear capsules, somewhat flattened, 10-20 cm 
long and 0.5-2 cm wide, brown at maturity, they split open to 
release numerous seeds, 3-5 mm each.  
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Fig No: 03  Fruit  of Tecomastans(L.)  
 
5.3.5. Seed  
Numerous. The seeds are very flat, oblong in shape (7-8 mm long 
and about 4 mm wide), and have a transparent wing at each end (the size 
of entire seed including the wings is about 20 x 6 mm) 
Fig No: 03 Seed of Tecomastans(L.)  
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5.3.5 Trunk 
 Tecomastans has a tendency to grow with several trunks. As an 
ornamental it can be trained to grow with a single trunks. The bark on the 
main trunk is light brown, hard, lose grained and become corky with age. 
 
5.4 Chemical Constituents 
 The plant contains triterpenes, hydrocarbons, resins and   volatile 
oil.  
1. Leaves contain flavanoids, chryseriol, Luteolin, Hyperoside, 
Indoleoxygenase. Alakloid like Tecomanine, Tecostamine, 4- 
noroctidine, N- hormethyl-skytarthine and S- skytanthine.  
2. Flowers contain p- carotene and  Zeaxanthin. Methanolic extract of 
the flowers showed the presence of flavonone , 7, 8 dihydroxy-5,6- 
dimethoxy flavones  and  Kaemperferol . 
3. Seeds contain fatty oil and the  compositionis plamitic acid, stearic 
acid octadecenoic acid, octadienoic acid, octadecatrienoic acid and 
octadeccatetranoic acid.  
4. Ethanolic extract of fruit contains monoterpenic alkaloids, 7- 
hydroxyskytenthine, 5-hydroxytecomanine, 5-hydroxyskytenthine . 
 
5.5 Medicinal Uses 
 Aerial parts used in the treatment of stomach problems, gastritis, 
diarrhoea 
 Roots are used as diuretic, vermifuge, tonic, beer making, a remedy 
in snakes bits, scorpion sting and  in  the treatment of syphilis . 
 Flowers possess narcotic and analgesic activity. 
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6. MATERIALS  AND METHOD 
6.1 Plant Material 
The plant leaves was collected locally from herbal store and 
botanical garden of the garden of the botany central council for Research 
Ayurvedicand Sidha Govt. of India .The plant was identified and 
authenticated by comparison with herbarium specimens.  
The leaf of Tecomastans (L.)juss ex kunth were authenticated by 
comparison with herbarium specimens and authentification  No. BSI/SRC 
5/23/2016/Tec/1993. 
The weighed coarse powder was used for the extraction by 
successive solvent extraction by Soxhlet apparatus using various solvents. 
6.2 Animals 
Wistar rats (150 – 250 g) used for the study were obtained from the 
animal house of the Department of Pharmacology, Karpagam College of 
Pharmacy, Coimbatore, Tamil Nadu. The animals are randomly selected, 
marked to permit individual identification, and kept in their cages for at 
least 5 days prior to dosing to allow for acclimatisation to the laboratory 
conditions. The animals were housed three per cage in a polypropylene 
cage and maintained in standard laboratory conditions with free access to 
food and water ad libitum18. All animal experiments were conducted in 
compliance with (Organization for Economic Cooperation and 
Development) OECD Guideline and approved by the Institutional Animal 
Ethics Committee, Karpagam College of Pharmacy 
6.3 Chemicals, Drugs and Instruments 
Streptozotocin, citric acid, sodium citrate were collected from a 
private chemical store Coimbatore (Ponmani and co). Other important 
chemical used in phytochemical analysis like alcohol, hydrochloric acid, ∞- 
napthol, Sulphuric acid, Fehling A&B, Benedict reagent, sodium hydroxide, 
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nitric acid, ammonia, lead acetate, ninhydrin, sudan red III reagent, 
glycerin, picric acid, chloroform, acetic anhydride, ferric chloride, zinc, 
dragendroff's reagent, Wagner’s reagent, Mayer’s reagent, sodium 
chloride and bromin water were collected from the store of Karpagam 
College of Pharmacy.  All the chemicals used in the study are of analytical 
grade. 
6.4 Extraction Procedure26 
The leaves of plant, dried under shade are carefully removed and 
grinded using a blender. The coarse power so obtained was used for the 
extraction by successive solvent extraction by Soxhlet apparatus using 
various solvents. The assembly of Soxhlet apparatus is as shown in the 
figure. 
Image No. 01: Extraction using soxhlet apparatus assembly 
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A. Alcoholic extract 
Marc obtained from the above extract was dried and extracted with 
2.5litres of ethanol (90%) in soxhlet apparatus for 36 hours .Then the 
extract obtained were collected and concentrated by vaccum distillation 
.The concentrated extract were then  dried by in a vaccum desciccator. 
6.5 Phytochemical Analysis27 
Phytochemicals are biologically active, naturally occurring chemical 
compounds found in plants, which provide health benefits for humans 
further than those attributed to macronutrients and micronutrients. Phyto-
constituents are the contributors of pharmacological activities of a plant. 
The individual extracts are subjected to qualitative tests for identification of 
various plant constituents.  
6.5.1 Test for Carbohydrates 
I. Molisch Test: To the aqueous extract, 1ml of ∝- napthol solution 
was  added and Conc. Sulphuric acid were added along the sides 
of the test  tube. 
II. Fehling Test: To the aqueous extract, equal quantities of Fehling  
 A & B were added .Upon heating gently. 
III. Benedict’s test: To 5ml of Benedict reagent, 8 drops of solution 
under test was added to the test solution mixed well. Then it was 
boiled vigorously for 2 minutes and cooled. 
6.5.2 Test for Proteins 
I. Biuret Test: To the aqueous extract, 1ml of 40% NaOH and 2 
drops of 1% copper sulphate solution was added. 
II. Xanthophoretic Test: To the aqueous extract, 1ml of conc. Nitric 
acid was added. When a white precipitate was formed, it is boiled 
and cooled. Then 20% of NaOH or ammonia was added. 
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III. Lead acetate Test: To the aqueous extract, 1ml of lead acetate 
 solution was added.  
 
6.5.3 Test for Amino acids 
 Ninhydrin Test: 2drops of freshly prepared 0.2% ninhydrin reagent 
was added to the aqueous extract and heated. 
6.5.4 Test for Fats and Oils  
Place a thick section of drug on glass slide. Add a drop of Sudan 
Red III reagent. After two minutes, wash with 50 % alcohol. Mount in 
glycerin. Observe under microscope.  
6.5.5 Test for Steroids 
I. Liebermann Burchard Test: The aqueous extract was dissolved in 
2ml chloroform in dry test tube. 10 drops of acetic anhydride and 2 
drops of conc. sulphuric acid were added.  
II. Salkowaski Test: The aqueous extract was dissolved in chloroform 
and equal volume of sulphuric acid was added to it.  
 
6.5.5 Test for Cardiac glycosides 
Keller-killiani Test: Test sample was dissolved in acetic acid 
containing traces of ferric chloride and transferred to the surface of 
conc. Sulphuric acid.  
6.5.7 Test for Saponins 
 Foam Test: About 1ml of aqueous extract is diluted separately with 
distilled water to 20ml and shaken in a graduated cylinder for 15 minutes.  
 
 
6.5.8 Test for Flavonoids 
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I. Sulphuric Acid Test: On addition of sulphuric acid (66% or 80%) 
flavons and flavonols dissolves into it and give a deep yellow 
solution. 
II. Heat the test solution with Zinc and HCl, pink to red colour 
observation shows the presence of flavonoids. 
 
6.5.9 Test for Alkaloids 
I. Dragendroff’s Test: To the aqueous extract, add 1ml of 
 Dragendroff’s reagent. 
II. Wagner’s Test: To the aqueous extract, add1 ml of Wagner’s 
 reagent.  
III. Mayer’s Test: To the aqueous extract, add 1ml of Mayer’s reagent.  
6.5.10  Test for Phenolic compounds and Tannins 
  Small quantities of alcoholic and aqueous extracts in water were 
tested for the presence of phenolic compounds and tannins with dilute 
ferric chloride solution (5%), 1% solution of gelatin containing 10% sodium 
chloride, 10% lead acetate and bromine solutions.  
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6.6 TOXICITY STUDIES 28,29,30 
Acute Toxicity Study 
Experimental Protocol: 
Guideline                      :  OECD-423 
CPCSEA Ref. No               :  KU/IAEC/M.Pharm/169 
Test                                  :  Limit test 
Species                              :  Rattusnorvegicus 
Strain                                 : Albino Wistar rats 
Number of animals         :  24 animals (6 for each group) 
Sex                                    :  Female 
Initial dose                     :  5mg/kg 
Route of administration :  Oral 
Duration                         :  3hr close observation, followed by  
  14 days observation 
Others                             :  Body weight, mortality status 
Parameters                    :  CNS, ANS and behavioural changes 
Blood collection            :  Not needed 
Sacrifice                         :  Not needed 
 
Table No. 02 : Experimental Design of Acute Toxicity Study 
 
 
GROUP Number of Animals DOSE (mg/kg) 
Group 1 6 5 
Group 2 6 50 
Group 3 6 300 
Group 4 6 2000 
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6.7 Selection of Test animals. 
Female adult wistar rats of 8-12 weeks are selected. Nulliparous 
and non-pregnant animals were obtained from the centralized animal 
house of Karpagam College of pharmacy, Coimbatore and they are 
acclimatized for holding 1 week prior to dosing. 
6.8 Housing and feeding conditions for Experimental Animals. 
Temperature - As per OECD guideline-420 the temperature of 
animal house were maintained at 23°C±5°C. 
Humidity - The relative humidity of animal room maintained at 50-
60% preferably not exceeds 70% (OECD guidelines-423, 2001). 
Otherwise there may be chances of developing lesions such as ring tail 
and food consumption may be increased. 
Light – The sequence of light used was 12 hrs light and 12 hrs 
dark. 
Caging – Polypropylene cages with solid bottom and walls. The lids 
are made up of stainless steel grill which is capable to hold both feed and 
water.  
Feeding condition and feed – Sterile laboratory feed (ad libitum) 
and water daily. The feed used were brown coloured chow diet. 
6.9 Drug administration  
Animals are fasted prior to dosing (food but not water should be 
withheld for overnight).After that animals are weighed and the test 
substance administered. The healthy rats has been taken and divided into 
4 different groups. The test substance was administered in a single dose 
by oral gavages, using a curved and ball tipped stainless steel feeding 
needle. 
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6.10 Experimental Design 
In this study, 4 groups of 6 rats each were given with 5, 50 and 300 
and 2000 mg/kg of the extract (p.o.). After drug administration the food is 
withheld for 3 hours. The animals are observed continuously for the first 2 
hours, then occasionally up to 6 hours and then daily up to 14 days, post 
treatment to observe for any symptoms of toxicity and mortality. Daily 
observations on the changes in skin and fur, eyes and mucus membrane 
(nasal), autonomic effects (salivation, lacrimation, gauntness 
andpiloerection) and central nervous system (gait, tremors and convulsion) 
were carried out and changes were noted (OECD, 2001). 
6.11 Clinical observation 
All animals were monitored continuously with special attention for 4 
hrs after dosing for signs of toxicity. Additional observations are also done 
for the next 14 days for any other behavioural or clinical signs of toxicity. 
Weight changes are calculated. At the end of the test animals are 
weighed. LD50 values are established using the formula. 
 
6.12 Dose Calculation Equation 
LD50= higher dose ─ Σ (a x b)/n 
    
Where, 
a = dose difference 
b = animal died 
n = No. of animals in each group 
    ED50=LD50 
    10 
6.13 Pharmacological Studies31 
6.13.1 Selection of Test animals. 
Male wistar rats weighing 150-200g were used for the present work. 
The animals used for the experiment were maintained under standard 
laboratory conditions in an animal house of Karpagam College of 
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Pharmacy approved by the committee for the purpose of control and 
supervision on experiments on animals (IAECNO.KU/IAEC/M.Pharm/169) 
under 12 h dark/light cycle and controlled temperature 24±2°C. They had 
free access to food and water ad libitum. The animals were acclimatized to 
the laboratory for a period of 7 days, before the commencement of 
experiment.  
6.13.2 Induction of Diabetes in Experimental Animals 
Experimental diabetes was induced by single intra-peritonial 
injection of  
25 mg/kg of streptozotocin (STZ), freshly dissolved in cold citrate buffer 
(pH 4.5) after 15 min of intra-peritonialinjection of nicotinamide (110 
mg/kg) prepared in normal saline. Rats with marked glycosuria (fasting 
blood glucose level greater than 200 mg/dL) after one week of 
administration of STZwere used for the study. 
6.14  Assessment of diabetes 
Diabetes was confirmed after 48 hr of streptozotocin injection, the 
blood samples were collected through tail vein and plasma glucose levels 
were estimated by glucose oxidase method (accu check active 
glucometer). The rats having fasting plasma glucose levels more than 
200mg/dL were selected and used for the present study. 
6.15 Glucose Tolerance Test 
  The Oral Glucose Tolerance test (OGTT) measures the body’s 
ability to use glucose, which is the body’s main source of energy. Oral 
glucose tolerance test was performed in overnight fasted (18 hours) 
normal rats.  
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6.16 Experimental Design 
  Normal rats were divided into four groups, each consisting of six 
rats. Group I was normal control (distilled water). Group II and III animals 
received different concentrations of extract viz., 200 mg/kg and 300 mg/kg 
respectively. Group IV animals are standard receiving Glibenclamide (GL) 
10 mg/kg body weight. Groups II and III animals were treated orally with a 
single dose of extract at a dose of 200mg/kg and 300 mg/kg p.o. 
respectively. Glucose (2 g/kg) was fed orally through oro-gastric tubes 30 
min after the administration of the drug. Control animals were administered 
with equal volume of water. Blood was withdrawn from the tail vein at 0, 1, 
2, 3 and 4 hr of glucose administration. The percentage induced glycaemia 
(%IG) following oral glucose load at different time intervals was calculated 
for the control and treated groups as follows. 
 
%IG  =  (Gx-Go)/Go × 10 
 
Where Go is the initial glycemia (mg/dL) and Gx the glycemia (mg/dL) at 
different time intervals after the oral glucose load. 
6.17 Hypoglycaemic Activity 
On the basis of the OGTT studies in normal and diabetic rats, 
dose was selected for STZ-induced diabetic rat model studies. 
6.18 Experimental Design: All hyperglycaemic rats were randomly 
divided into four groups of six rats in each groups, 24rats (18 diabetic rats 
and 6 normal rats). 
 
Group I – Normal control (Distilled Water) 
Group II – Diabetic control (Distilled Water) 
Group III – Streptozotocin + Glibenclamide (10 mg/kg p.o) 
Group IV – Streptozotocin + Ethanolic extract (300 mg/kg p.o.) 
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The test drug was administered orally using an oral feeding needle 
once daily for 28 days. The body weight, food and water intake behaviour 
of the animals were measured at the onset of the study and at the regular 
intervals of every week up to 28 days. 
 
Group I animals (normal rats) were administered orally with 
distilled water whereas group II animals (diabetic) received distilled water, 
group III animals (diabetic) received glibenclamide (10 mg/kg p.o)  and 
group IV animals (diabetic) received extract 300 mg/kg body weight for 
28 consecutive days.  
 
The blood samples collected from the tail vein of rats on 0, 7, 14, 
21 and 28 days after administration of formulation. The blood glucose 
levels were determined by the glucose oxidase method using glucometer 
(Accucheck active). 
6.19 Statistical Analysis 
All values are expressed as mean ± SEM. Statistical analysis was 
performed by One-way Anova, analysis of variance (ANOVA) followed by 
Dunnet’s t-test. A ‘p’ value less than 0.05 was considered significant. 
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 7. RESULTS AND DISCUSSION 
7.1.  EXTRACTION 
The dried powdered course blend of leaf form TecomaStansare 
undergone successive solvent extraction using alcohol and water as 
solvents. A comparatively greater extractive value was obtained in 
alcoholic extract of the leaf. 
Table No. 01 : SOXHLET EXTRACTION OF TECOMASTANS (L.)  
juss. EX KUNTH 
Plant 
Part 
used 
Method of 
Extraction 
Solvents 
Average value of 
extractive(%W/V) 
TecomaStans(L.) 
juss.exkunth 
Dried 
Leafs 
Continuous 
Hot 
percolation 
by Soxhlet 
apparatus 
Ethanol 
(50%) 
33.2% 
 
7.2.  PHYTOCHEMICAL EVALUATION  
 Phytochemicals are bioactive substances of plants that have been 
associated in the protection of human health against chronic degenerative 
diseases39. Phytochemical analysis of ethanol extract shows alkaloids, 
carbohydrates, saponins, proteins, amino acids, flavonoids and tannins. 
The combination of above mentioned phytochemicals may be the reason 
behind the ant diabetic properties of the plant. 
7.2.1. Test for Carbohydrates 
I. Molisch Test:  
Purple or reddish violet colour at the junction between the two 
liquids indicates the presence of carbohydrates. 
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II. Fehling Test:  
 A brick red precipitate indicates the presence of carbohydrates. 
III. Benedict’s test: 
 Red precipitate indicates the presence of carbohydrates. 
7.2.2. Test for Proteins 
I. Biuret Test:  
 A violet colour indicates the presence of proteins. 
II. Xanthophoretic Test:  
Orange colour indicates the presence of aromatic acids. 
III. Lead acetate Test: 
 A white precipitate indicates the presence of proteins. 
7.2.3  Test for Amino acids 
I.  Ninhydrin Test: 
A  blue colour indicates the presence of proteins, peptides or amino 
acids. 
7.2. 4. Test for Fats and Oils  
I.  Red globules in the section when viewed under the microscope 
show the presence of fats or oils. 
7.2.5. Test for Steroids 
I. Layer assumes marked green fluorescence indicates the presence 
 of steroids. 
7.2.6. Test for Cardiac glycosides 
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II. Keller-killiani Test:  
 At the junction, reddish brown colour was formed, which gradually 
becomes blue indicates the presence of cardiac glycosides. 
7.2.7. Test for Saponins 
I. Foam Test:  
 A1cm layer of foam indicates the presence of saponins.. 
7.2.8. Test for Alkaloids 
I. Dragendroff’s Test:  
 An orange red coloured precipitate indicates the presence of 
alkaloids. 
 
II. Wagner’s Test:  
Reddish brown coloured precipitate indicates the presence of 
alkaloids. 
III. Mayer’s Test:  
 A dull white coloured precipitate indicates the presence of 
alkaloids. 
7.2.9. Test for Phenolic compounds and Tannins 
I.  The respective observations may be deep blue black colour, white 
precipitate, white precipitate, decolouration of bromine water 
showing the presence of tannins and phenolic compounds. 
 
 
 
 
Table  No.02:  preliminary phytochemical evaluation of Tecomastans 
(l.) juss. exKunthleaf extracts 
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S.No Phytoconstituents Ethanol 
1 Alkaloids + 
2 Carbohydrates & Glycosides + 
3 Phytosterols _ 
4 Fixed oils - 
5 Saponins + 
6 Tannins and Phenols + 
7 Proteins and Amino acids + 
8 Gums and Mucilage’s - 
9 Flavonoids + 
10 Tannins’s + 
(+) – Presence, (-) – Absence 
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7.3.  ACUTE TOXICITY STUDY 
There were no mortality or signs of toxicity up to the limit dose of 
2000 mg/kg in treated rats. All 24 rats were normal throughout the study 
and survived until the end of the 14-day experiment period. Animal 
wellness parameters were observed continuously for the first 2 hours, then 
occasionally up to 6 hours and then daily up to 14 days as per paragraph 
24 and 25 of OECD Guideline 423. Experimental observations are 
recorded systematically for each group. The parameters considered are 
changes in skin and fur, eyes and mucous membrane and also respiratory 
and circulatory, autonomic and central nervous system, somatomotor 
activity and behavioral pattern. Special attention is given for the 
observations of tremor, convulsion, salivation, diarrhoea, lethargy, sleep 
and coma. 
Table No: 03-Changes in wellness parameters observed for ethanolic 
extracttreated wistar rats. 
Sl 
no 
Response 
Group1(5mg/kg) 
Group 2 
(50mg/kg) 
Group 3 
(300mg/kg) 
Group 4 
(2000mg/kg) 
Before After Before After Before After Before After 
1 Alertness Normal Normal Normal Normal Normal Normal Normal Normal 
2 Grooming Absent Absent Absent Absent Absent Absent Absent Absent 
3 Anxiety Absent Absent Absent Absent Absent Absent Absent Absent 
4 Roaming Normal Normal Normal Normal Normal Normal Normal Normal 
5 Tremor Absent Absent Absent Absent Absent Absent Absent Absent 
6 Convulsion Absent Absent Absent Absent Absent Absent Absent Absent 
7 Depression Normal Normal Normal Normal Normal Normal Normal Normal 
8 
Gripping 
strength 
Normal Normal Normal Normal Normal Normal Normal Normal 
9 Scratching Present Present Present Present Present Present Present Present 
10 Defecation Normal Normal Normal Normal Normal Normal Normal Normal 
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Sl 
no 
Response 
Group1(5mg/kg) 
Group 2 
(50mg/kg) 
Group 3 
(300mg/kg) 
Group 4 
(2000mg/kg) 
Before After Before After Before After Before After 
11 Writhing Absent Absent Absent Absent Absent Absent Absent Absent 
12 Pupils Normal Normal Normal Normal Normal Normal Normal Normal 
13 Urination Normal Normal Normal Normal Normal Normal Normal Normal 
14 Salivation Normal Normal Normal Normal Normal Normal Normal Normal 
15 Skin and fur Normal Normal Normal Normal Normal Normal Normal Normal 
16 Lacrimation Normal Normal Normal Normal Normal Normal Normal Normal 
17 Pilo erection Absent Absent Absent Absent Absent Absent Absent Absent 
18 Nail status Normal Normal Normal Normal Normal Normal Normal Normal 
19 Gauntness Normal Normal Normal Normal Normal Normal Normal Normal 
20 Gait Normal Normal Normal Normal Normal Normal Normal Normal 
21 Diarrhoea Absent Absent Absent Absent Absent Absent Absent Absent 
22 Sleep Normal Normal Normal Normal Normal Normal Normal Normal 
23 Coma Absent Absent Absent Absent Absent Absent Absent Absent 
24 Lethargy Normal Normal Normal Normal Normal Normal Normal Normal 
25 
Mucous 
membrane 
Normal Normal Normal Normal Normal Normal Normal Normal 
(+) – Presence, (-) – Absence 
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7.4. PHARMAACOLOGICAL STUDIES 
7.4.1. Effect of ethanolic extract on Glucose-Loaded Rat (OGTT Model) 
 
Vehicle treated group and GL (10 mg/kg body wt) treated group 
showed significantly rise in serum glucose level (SGL) after one hour of 
glucose administration, whereas groups II and III showed significantly 
increase in SGL respectively. From the study, it is found that both 200 
mg/kg and 400 mg/kg of ethanolic extract possess significant 
hypoglycemic activity in normal rats. It is found that 200 mg/kg of ethanolic 
extract showed a significant reduction in blood glucose at second hour and 
400 mg/kg of ethanolic extract shows more significant reduction at the 
same time interval compared  to control group and GL group respectively, 
shown in Table No 4. Hence, ethanolic extract 400 mg/kg dose was 
selected for further study in STZ-induced diabetic rat model. However, all 
groups of animals almost normalized the SGLs within three hours 
indicating that the pancreas of animals was healthy to clear out the 
glucose load from the body. 
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Table No.4: - Effect of ethanolic extract on serum glucose levels in 
OGTT model in normal rats 
Values are represented as mean ± SEM (n=6 rats). 
Values are statistically significant at *P < 0.05,** P < 0.01. 
GL = Glibenclamide. 
Graph 1 - Effect of ethanolic extract on serum glucose levels in OGTT 
model in normal rats 
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Group I Control (Distilled water) Group II Etract (200 mg/kg)
Group III extract (300 mg/kg) Group IV GL (10 mg/kg body Wt)
S.No 
Drug/Control 
Body 
weight 
Blood glucose level 
(mg/dL) 
 0 hour 1 hour 2 hour 3 hour 4 hour 
1 
Group-1 
control(distil
led water) 
180.0
±2.0 
92.0± 
2.5 
132.0
±3.5 
117.0±
0 
119.0±
1.0 
100.5±
1.5 
2 
Group-2 
extract 
(200mg/kg) 
164.1
±2.7 
102.0
±1.0 
** 
123±0 
** 
107.0±
2.0 
** 
101.0±
3.0 
* 
98.0± 
2.0 
* 
3 
Group-3 
exotract 
(400mg/kg) 
152.6
±3.4 
99.0±
1.5 
** 
120.0
±1.5 
** 
100.0±
2.5 
** 
96.0± 
3.0 
* 
88.5± 
1.5 
* 
4 
Group-4 GL 
(10 mg/kg 
body wt) 
151.3 
±2.3 
111.0
±4.5 
** 
121.0
±3.1 
** 
117.0±
3.6 
** 
114.0±
2.6 
* 
112.5±
1.2 
* 
4 
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7.4.2. Effect of ethanolic extract on serum glucose level of diabetic 
 rats 
Diabetic control rats showed consistent and gradual rise in SGL 
during the study. GL (10 mg/kg body wt) and ethanolic extract 400 mg/kg 
treated rats showed a significant  reduction 7th, 14th, 21st, and 28th day 
of the study and the results were found to be statistically significant 
(P<001) as compared to diabetic control which is shown in Table 5. The 
effect was found to be time dependent up to 28th day of the study. 
Decrease in SGL was more significant (P<0.001) on 28th day when 
compared with standard drug. 
 
Table No. 5: - Effect of 27 days treatment of ethanolic extract on 
serum glucose levels of STZ-induced diabetic rats 
S.N
o 
Treatment Initial 7th day 
14th 
day 
21stday 
28th 
day 
1 Normal control 89.3±3.8 
91.0± 
1.5 
95.0±1.
0 
92.8± 
2.1 
89.0± 
1.7 
2 Diabetic control 
221.5±3.
2 
267.3± 
3.5 
310.3± 
2.2 
383.0± 
2.8 
405.3± 
3.2 
3 
Diabetic+Gliben
clamide 
(10mg/kg) 
281.0±1.
9 
*** 
261.0± 
3.6 
** 
153±3.
8 
*** 
140.1± 
3.1 
*** 
129.5± 
2.7 
*** 
4 
Diabetic+ 
extract 
(400 mg/kg) 
240.1±2.
2 
*** 
210.6± 
3.3 
*** 
160.3± 
3.7 
*** 
121.3± 
1.4 
*** 
96.8± 
1.7 
*** 
Values are represented as Mean ± SEM (n=6 rats). 
Values are statistically significant at ** P < 0.01, *** P < 0.001. Diabetic + 
ethanolic extract compared with diabetic + glibenclamide and normal 
control rats. 
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Graph: 2 - Effect of 27 days treatment of ethanolic extract on serum 
glucose levels of STZ-induced diabetic rats 
 
 
 
 
7.4.3. Effect of ethanolic extract treatment on body weight 
There was also a significant reduction in body weight in diabetic 
animals, however, the animals treated with 400 mg of ethanolic extract 
and GL showed significant (P<0.001) check on the loss of body weight on 
days 21 and 28 in comparison to the day of onset of the study. This effect 
may be attributed to increased insulin secretion and food consumption. 
These results implied that the developed ethanolic extract can reduce the 
complications of body weight and associated cardiovascular risk factors 
during diabetes. 
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Table No.6: - Effect of ethanolic extract treatment on body weight in 
STZ-induced diabetic rats on 21st day and 28th day 
S.No Drug/Control 
Body weight(g) 
Baseline 21st day 28th day 
1 Normal control 180.0±2.0 180.9±3.2 182.2±3.1 
2 Diabetic control 164.1±7.1 155.0±7.0 
123±10.2 
** 
3 
Diabetic+ 
Glibenclamide 
(10mg/kg) 
152.6±8.4 
153.8±9.5 
** 
155.1±6.7 
*** 
4 
Diabetic + extract 
(400mg/kg) 
151.3 ±7.3 
152.0±5.1 
** 
156.0±7.3 
*** 
Values are represented as Mean ± SEM (n=6 rats). 
Values are statistically significant at ** P < 0.01, *** P < 0.001. Diabetic + 
ethanolic extract compared with diabetic + glibenclamide and normal 
control rats.  
 
Graph 3 :- Effect of ethanolic extract treatment on body weight in 
STZ-induced diabetic rats on 21st day and 28th day 
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The body’s ability to maintain the glycemic level may be measured 
by OGTT in normal rats. The method is usually used to test DM, insulin 
resistance, beta cell function40 and sometime reactive hypoglycaemia, 
acromegaly or rarer disorders of carbohydrate metabolism. Glucose 
tolerance was first described in 1923 by Jerome etal41. In the present 
study the blood samples were collected at a time interval of 0, 1, 2, 3 & 4 
hours. The glycemic level of extract treated groups at different doses are 
compared with control groups. Vehicle treated group and Glibenclamide 
(10 mg/kg body weight) treated group showed 43.4% and 9.0% rise in 
serum glucose level (SGL) after one hour of glucose administration 
whereas groups II and III showed 20.5% increase and 21% increase in 
SGL respectively. From the study, it was found out that both 200 mg/kg 
and 400 mg/kg of extract possess significant hypoglycemic activity in 
normal rats. It is found that 200 mg/kg of extract showed a 13% reduction 
in blood glucose at second hour and 400 mg/kg of ethanolic extract shows 
16.5 % reduction at the same time interval compared to 11.3% decrease 
and 3.4% decrease in control group and GL group respectively. Hence, 
ethanolic extract of 400 mg/kg dose was selected for further study in STZ-
induced diabetic rat model. However, all groups of animals almost 
normalized the SGLs within three hours indicating that the pancreas of 
animals was healthy to clear out the glucose load from the body. 
 
After OGTT the anti-hyperglycemic effect of ethanolic extract was 
checked in streptozotocin induced diabetic Wistar rats after an 18 hours 
fasting. Glibenclamide 10 mg/kg is used as a standard. The diabetic rats 
were subjected for 28 days study ad libitum. Diabetic control rats showed 
consistent and gradual rise in SGL during the study. GL (10 mg/kg body 
weight) and extract 400 mg/kg treated rats showed a reduction in SGL. 
Diabetic control rats showed consistent and gradual rise in SGL during the 
study. GL (10 mg/kg body wt) and extract 400 mg/kg treated rats showed 
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a reduction in SGL by 7.1%, 45.5%, 50.1, 53.9%; and 12.3%, 33.3%, 
49.5%, 59.7% on 7th, 14th, 21st, and 28th day of the study and the results 
were found to be statistically significant (P<001) as compared to diabetic 
control. The effect was found to be time dependent up to 28th day of the 
study. Decrease in SGL was more significant (P<0.001) on 28th day when 
compared with standard drug. 
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8. SUMMARY AND CONCLUSION 
 The current anti-diabetic drug research is facing complex 
challenges.  As times go on it demands an integrated approach towards 
the health care system.There has been a growing interest in natural 
medicinal plantrelated research37. They are many difference in their 
philosophical and epistemological foundation concerted frame work and 
practical outlook. In case of diabetes both the system of medicine have 
different type of treatment approaches based on the severity of the 
diseases. By using medicines reduces the signs and symptoms of the 
disease. Once diabetes mellitus is diagnosed, the patient should take 
medication lifelong. In modern medical system long duration treatment of 
diabetes is risky, because the side effects of the drugs are severe. But in 
the case of ayurvedic medical system the side effects of drugs are less 
compared to modern medical system, because they are natural in origin. 
 Phytochemicals are bioactive substances of plants that have been 
associated in the protection of human health against chronic degenerative 
diseases27. Phytochemical analysis of ethanol extract shows alkaloids, 
carbohydrates, saponins, proteins, amino acids, flavonoids and tannins. 
The combination of above mentioned phytochemicals may be structural 
similarity of compound of the pant.  
 In the toxicity studies ethanolic extract did not show any signs or 
symptoms of toxicity in rats at doses up to 2000 mg/kg p.o., indicating that 
it has no toxicity at the maximal doses tested in this work. Although herbal 
medicinal products are widely considered to be of lower risk compared 
with synthetic drugs, they are not completely free from the possibility of 
toxicity or other adverse effects40. Thus, toxicological evaluation of plants 
derived products, including extracts forms an essential part of scientiﬁc 
validation of medicinal plants. Although, poisonous plants are ubiquitous41, 
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herbal medicine is used by up to 80% of the population in the developing 
countries. The safety of herbal medicine use has recently been questioned 
due to reports of illness and fatalities like nephrotoxicity and 
hepatotoxicity42-43. 
 The acute toxicity study indicated that ethanolic extract at a dose 
2000 mg/kg caused neither visible signs of toxicity nor mortality. The LD50 
and ED50 of the drug were estimated as 2000 mg/kg and 200 mg/kg 
respectively. If LD50 is 2000 mg/kg, it could be generally regarded as safe 
(GRAS). This finding is in agreement with Clarke and Clarke45, who 
reported that any compound or drug with oral LD50 estimates greater than 
1000 mg/kg body weight could be considered to be of low toxicity and 
safe. However, it is suggested that variables such as animal species, 
strain, age, gender, diet, bedding, ambient temperature, caging conditions, 
and time of the day can all affect the LD50 values obtained and as such are 
considerable uncertainties in extrapolating the LD50 obtained for species to 
other species. This finding is suggestive that LD50 may not be considered 
as a biological constant 46. 
 Oral administration of ethanolic extract at doses of 200, 500, or 
1000 mg/kg body weight daily for 28 day did not produce any signs of 
toxicity or mortality. The animals did not show any changes in general 
behavior or other physiological activities and were found normal 
throughout the study. 28 day study provides information on the effects of 
repeated oral exposure and can indicate the need for further longer term 
studies. It can also provide information on the selection of concentrations 
for longer term studies. All animals are observed for morbidity and 
mortality twice daily. Little or no change was observed in body weight, food 
consumption, and water intake in ethanolic extract (200, 500 and 
1000 mg/kg)-treated groups compared with control group after 28 days of 
study period in rats. All animals are weighed before starting the 
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experiment and once in a week. Measurements of food and water 
consumption are also made once weekly. Ethanolic extract caused a 
statistically significant (P <0.01) rise in body weight among group III 
animals. It is necessary to measure the water consumption at least 
weekly. No signs and symptoms of toxicity, changes in behavior or other 
physical and physiological abnormalities were observed during the 
experimental period. 
Streptozotocin is probably the most widely used agents producing 
insulin-dependent diabetes mellitus and non-insulin dependent diabetes 
mellitus in experimental animals. It is a glucosamine nitrosourea 
compound54 causes beta cells of islets of Langerhans of rats to clearly 
degenerate. In three days, Streptozotocin makes pancreas swell and at 
last causes degeneration in beta cells of islets of Langerhans and induces 
experimental diabetes. It also changes normal metabolism in diabetic rats 
in comparison with normal rats. Prolonged administration of STZ might 
have reduced the beta calls of islets of Langerhans to produce insulin. The 
observed blood glucose lowering effect of the decoction in STZ induced 
diabetic rats could also possibly due to increase peripheral glucose 
utilization. A number of other plant have also been shown to exert 
hypoglycemic activity through stimulation of insulin release.55,56 
  Consumption of water and food, volume of urine, serum glucose 
increases in diabetic animals in comparison with normal rats, but the 
levels of serum insulin, C-peptide and body weight decreases.55 The 
characteristic loss of bodyweight is due to increased muscle wasting in 
diabetes. 56When diabetic rats were treated with extract, the weight loss 
was put on check and reversed. 
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The different extracts (alcoholic and aqueous) of TecomaStanswere 
subjected to physicochemical analysis. Tests for carbohydrates, phenols, 
tannins, alkaloids, flavonoids, fats, glycosides, steroids, amino acids, 
proteins carbohydrates, proteins, amino acids, flavonoids, saponins, 
phenol and tannins which may probably responsible for their expected 
pharmacologic action. The extract with maximum number of phyto-
constituents and extractive value identified (ethanolic) is used in the further 
evaluations. Toxicity study shows the safety nature of the extract and also 
acute and sub-acute toxicity study do not produce any toxic symptoms 
upto 500 mg/kg. 
The extract was pre-clinically evaluated against STZ induced 
diabetic rats models for its antidiabetic activity. The extract showed insulin 
mimetic activity and control of blood sugar level which are comparable to 
the reference drug glibenclamide at a dose of 10mg/kg. as the invivo 
results indication has been concluded 50% ethanolic extract of Techoma 
Stanus (L), which may be containing structurally insulin resembled 
compounds. In conclusion the extract is safe and can be used to treat 
diabetic condition without any harmful effects. Further studies are required 
to confirm the exact mechanism behind the antidiabetic activity of the 
extract. 
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